|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...108109110111112113114115116117118...156157» |
- | Lemtrada (alemtuzumab) / Sanofi
Enrollment closed, MRI, Metastases: iCAMMS-IST: Advanced MRI Measures of Repair in Alemtuzumab Treated Patients (clinicaltrials.gov) - Dec 9, 2013
P3, N=25, Active, not recruiting, Sponsor: University of British Columbia
Enrolling by invitation --> Active, not recruiting
- | Humira (adalimumab) / Eisai, AbbVie
Trial completion: BROCA: Bone Resorption, Osteoclastogenesis and Adalimumab (clinicaltrials.gov) - Dec 9, 2013
P=N/A, N=28, Completed, Sponsor: Université de Sherbrooke
Enrolling by invitation --> Active, not recruiting Recruiting --> Completed
- || Enrollment change: An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes (clinicaltrials.gov) - Dec 9, 2013
P=N/A, N=23606, Completed, Sponsor: Novo Nordisk
Recruiting --> Completed N=6300 --> 23606
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Dec 9, 2013
P1, N=36, Completed, Sponsor: Novo Nordisk
N=6300 --> 23606 Active, not recruiting --> Completed
- Trial completion: Intervention With Long-chain n-3 Polyunsaturated Fatty Acids From Microalgae Oil in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Dec 9, 2013
P=N/A, N=35, Completed, Sponsor: University of Jena
Active, not recruiting --> Completed Recruiting --> Completed
- ||| Trial completion: An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes (clinicaltrials.gov) - Dec 9, 2013
P=N/A, N=23606, Completed, Sponsor: Novo Nordisk
Recruiting --> Completed Enrolling by invitation --> Completed
- ||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Combination therapy: A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy (clinicaltrials.gov) - Dec 8, 2013
P3, N=15, Completed, Sponsor: Hoffmann-La Roche
- AMP-110 / AstraZeneca, Daiichi Sankyo
Enrollment closed: Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Dec 7, 2013
P1, N=21, Active, not recruiting, Sponsor: Amplimmune
Enrolling by invitation --> Completed Recruiting --> Active, not recruiting
- Clinical: Screening of Subjects With Type I Diabetes to Determine Eligibility for Islet Transplantation (clinicaltrials.gov) - Dec 5, 2013
P=N/A, N=600, Recruiting, Sponsor: Rodolfo Alejandro
- |||||||||| Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
New P2/3 trial: Phase II Study to Evaluate the Efficacy and Safety of Glassia (clinicaltrials.gov) - Dec 5, 2013
P2/3, N=192, Recruiting, Sponsor: Kamada, Ltd.
- Benlysta (belimumab) / GSK
Trial withdrawal: Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy (clinicaltrials.gov) - Dec 4, 2013
P2, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Recruiting --> Withdrawn
- Benlysta (belimumab) / GSK
Enrollment change: Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy (clinicaltrials.gov) - Dec 4, 2013
P2, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Recruiting --> Withdrawn N=94 --> 0
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes (clinicaltrials.gov) - Dec 4, 2013
P1, N=44, Completed, Sponsor: Novo Nordisk A/S
- Enrollment open: Closed-loop Control of Glucose Levels (Artificial Pancreas) for 60 Hours in Adults With Type 1 Diabetes (clinicaltrials.gov) - Dec 4, 2013
P2, N=20, Recruiting, Sponsor: Institut de Recherches Cliniques de Montreal
N=94 --> 0 Not yet recruiting --> Recruiting
- Trial completion, Surgery: Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease (clinicaltrials.gov) - Dec 4, 2013
P=N/A, N=10, Completed, Sponsor: Sensimed AG
Not yet recruiting --> Recruiting Recruiting --> Completed
- Enrollment change: Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE) (clinicaltrials.gov) - Dec 3, 2013
P=N/A, N=20, Completed, Sponsor: Spirig Pharma Ltd.
Recruiting --> Completed N=70 --> 20
- |||||||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
New P3 trial: A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy (clinicaltrials.gov) - Dec 3, 2013
P3, N=130, Recruiting, Sponsor: Hoffmann-La Roche
- ||| fletikumab (NNC109-0012) / Novo Nordisk
Enrollment closed: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate (clinicaltrials.gov) - Dec 3, 2013
P2, N=268, Active, not recruiting, Sponsor: Novo Nordisk
N=70 --> 20 Recruiting --> Active, not recruiting
- | Trial completion: Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE) (clinicaltrials.gov) - Dec 3, 2013
P=N/A, N=20, Completed, Sponsor: Spirig Pharma Ltd.
Recruiting --> Active, not recruiting Recruiting --> Completed
- mycophenolate mofetil / Generic mfg., azathioprine / Generic mfg.
Trial withdrawal: Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens (clinicaltrials.gov) - Dec 3, 2013
P2, N=0, Withdrawn, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed Recruiting --> Withdrawn
- mycophenolate mofetil / Generic mfg., azathioprine / Generic mfg.
Enrollment change: Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens (clinicaltrials.gov) - Dec 3, 2013
P2, N=0, Withdrawn, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Withdrawn N=20 --> 0
- | Trial completion: A Trial Investigating the Effect of Acute Hypoglycaemia on Cognitive Function and Brain Activation Patterns in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Dec 3, 2013
P1, N=27, Completed, Sponsor: Novo Nordisk
N=20 --> 0 Recruiting --> Completed
- || Humira (adalimumab) / Eisai, AbbVie
Trial initiation date, HEOR: AGIL: Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Dec 2, 2013
P=N/A, N=4500, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed Initiation date: Jul 2008 --> Jan 2009
- |||| atacicept (VT-001) / Vera Therap
Enrollment open: ADDRESS II: Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus (clinicaltrials.gov) - Dec 2, 2013
P2b, N=279, Recruiting, Sponsor: EMD Serono
Initiation date: Jul 2008 --> Jan 2009 Not yet recruiting --> Recruiting
- Trial completion, HEOR: Foot Orthoses (FOs) on Pain, Quality of Life and the Gait With Children Diagnosed With JIA (clinicaltrials.gov) - Dec 2, 2013
P=N/A, N=60, Completed, Sponsor: University of Newcastle, Australia
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- Trial withdrawal: Efficacy of Small Subcutaneous Glucagon Dose to Treat Hypoglycemia in Adults With Type 1 Diabetes (clinicaltrials.gov) - Dec 2, 2013
P2, N=0, Withdrawn, Sponsor: Institut de Recherches Cliniques de Montreal
Not yet recruiting --> Completed Recruiting --> Withdrawn
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment change: A Non-Interventional Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Dec 2, 2013
P=N/A, N=300, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Withdrawn N=200 --> 300
- Uplizna (inebilizumab) / Horizon Therapeutics, Mitsubishi Tanabe
Enrollment change: Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Dec 2, 2013
P1, N=28, Recruiting, Sponsor: MedImmune LLC
N=200 --> 300 N=88 --> 28
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed: An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study (clinicaltrials.gov) - Dec 2, 2013
P3, N=11, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=88 --> 28 Recruiting --> Active, not recruiting
- |||||| tregalizumab (BT-061) - ADMA Biologics, T / Balance Therapeutics
New P2b trial, Combination therapy: Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis (clinicaltrials.gov) - Dec 1, 2013
P2b, N=304, Recruiting, Sponsor: Biotest
- |||| tregalizumab (BT-061) - ADMA Biologics, T / Balance Therapeutics
Enrollment open, Combination therapy: Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis (clinicaltrials.gov) - Dec 1, 2013
P2b, N=304, Recruiting, Sponsor: Biotest
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P3 trial: onset (clinicaltrials.gov) - Dec 1, 2013
P3, N=36, Active, not recruiting, Sponsor: Novo Nordisk A/S
- Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
Enrollment open: Continuous Subcutaneous Hydrocortisone Infusion In Addison's Disease and Type 1 Diabetes (clinicaltrials.gov) - Nov 28, 2013
P2, N=10, Recruiting, Sponsor: Haukeland University Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Humira (adalimumab) / Eisai, AbbVie
Enrollment open: Impact of Adalimumab Therapy on Brachial Endothelial Function and Large Artery Stiffness in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Nov 27, 2013
P3, N=60, Recruiting, Sponsor: Assistance Publique Hopitaux De Marseille
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- | Enrollment change: A Study of Rabeprazole for Prevention of Non Steroidal Anti-inflammatory Drug -Associated Gastroduodenal Injury (clinicaltrials.gov) - Nov 26, 2013
P3, N=112, Active, not recruiting, Sponsor: Chinese University of Hong Kong
Active, not recruiting --> Recruiting N=160 --> 112
- | meloxicam / Generic mfg.
Trial completion: This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets. (clinicaltrials.gov) - Nov 26, 2013
P2, N=28, Completed, Sponsor: GlaxoSmithKline
N=160 --> 112 Not yet recruiting --> Completed
- ||| Baqsimi (glucagon intranasal dry powder) / Amphastar
New P2/3 trial: Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Nov 26, 2013
P2/3, N=48, Recruiting, Sponsor: T1D Exchange Clinic Network Coordinating Center
- ||| insulin peglispro (LY2605541) / Eli Lilly
Trial completion: A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes (clinicaltrials.gov) - Nov 26, 2013
P1, N=76, Completed, Sponsor: Eli Lilly and Company
Not yet recruiting --> Completed Active, not recruiting --> Completed
- |||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment open, Combination therapy, Monotherapy: A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - Nov 25, 2013
P3, N=100, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| lansoprazole / Generic mfg., cyclosporine / Generic mfg.
Trial initiation date: The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Lansoprazole for Insulin Independence Among Patients With Existing Type 1 Diabetes (clinicaltrials.gov) - Nov 25, 2013
P3, N=60, Not yet recruiting, Sponsor: Perle Bioscience, LLC.
Not yet recruiting --> Recruiting Initiation date: Sep 2013 --> Sep 2014
- ||||| omeprazole / Generic mfg., cyclosporine / Generic mfg.
Trial initiation date: The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Omeprazole for Insulin Independence Among Recent Onset Type 1 Diabetes Patients (clinicaltrials.gov) - Nov 25, 2013
P3, N=60, Not yet recruiting, Sponsor: Perle Bioscience, LLC.
Initiation date: Sep 2013 --> Sep 2014 Initiation date: Sep 2013 --> Feb 2014
- Trial termination: Evaluation of Angioplasty in the Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis (clinicaltrials.gov) - Nov 24, 2013
P=N/A, N=18, Terminated, Sponsor: Community Care Physicians, P.C.
Initiation date: Sep 2013 --> Feb 2014 Recruiting --> Terminated; Inability to enroll adequate number of patients
- Enrollment change: Evaluation of Angioplasty in the Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis (clinicaltrials.gov) - Nov 24, 2013
P=N/A, N=18, Terminated, Sponsor: Community Care Physicians, P.C.
Recruiting --> Terminated; Inability to enroll adequate number of patients N=130 --> 18
- |||||||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
New P3 trial, Combination therapy, Monotherapy: A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Nov 24, 2013
P3, N=420, Recruiting, Sponsor: Hoffmann-La Roche
- NN9828 / Novo Nordisk
Enrollment change: An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Nov 24, 2013
P1, N=10, Terminated, Sponsor: Novo Nordisk A/S
N=130 --> 18 N=40 --> 10
- New P1/2 trial, Metastases: Body Weight Supported Treadmill Training in Persons With Multiple Sclerosis (clinicaltrials.gov) - Nov 21, 2013
P1/2, N=24, Recruiting, Sponsor: University of Illinois at Urbana-Champaign
- New P1 trial: FlexToBa for People With Multiple Sclerosis (clinicaltrials.gov) - Nov 21, 2013
P1, N=60, Recruiting, Sponsor: University of Illinois at Urbana-Champaign
- | Enrollment closed: Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS) (clinicaltrials.gov) - Nov 21, 2013
P2/3, N=56, Active, not recruiting, Sponsor: Department of Veterans Affairs
N=40 --> 10 Recruiting --> Active, not recruiting
- IO biomarker: GENIAL: GENetic & Immunologic Abnomalies in Systemic Lupus Erythematosus (clinicaltrials.gov) - Nov 21, 2013
P=N/A, N=60, Recruiting, Sponsor: Hospices Civils de Lyon
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Nov 21, 2013
P1, N=48, Completed, Sponsor: Novo Nordisk